Trials / Withdrawn
WithdrawnNCT05165849
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Multicenter, Open-label, Phase I/Ⅱ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFS101A in Combination With Toripalimab Treating Patients With Advanced Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GFS101A | GFS101A will be administrated intravenously Q3W. |
| DRUG | Toripalimab | Toripalimab with fixed dose of 240 mg Q3W administered intravenously. |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
- First posted
- 2021-12-21
- Last updated
- 2022-05-20
Source: ClinicalTrials.gov record NCT05165849. Inclusion in this directory is not an endorsement.